KOD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kodiak Sciences Inc (KOD) is not an ideal buy for a beginner investor with a long-term strategy at this moment. While the technical indicators show bullish momentum and analysts have a positive outlook with increased price targets, the significant insider selling and lack of recent news or congress trading data raise concerns. Additionally, the stock's historical trend suggests potential short-term downside, which may not align with the user's impatience for optimal entry points.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 66.5, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 36.404), which could limit immediate upside potential.
Analysts have upgraded the stock with higher price targets, citing strong results from the GLOW2 trial and improved safety/efficacy of the drug. The potential acceleration of Biologics License Application timing is another positive catalyst.
Insider selling has increased significantly (45259.39% over the last month), which could indicate a lack of confidence from those closest to the company. Additionally, there is no recent news or congress trading data to support a strong buy case.
No financial data available for the latest quarter.
Analysts are bullish on the stock, with recent upgrades and price targets ranging from $56 to $80. Positive trial results and improved drug formulations are driving optimism.
